Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus

Drugs of Today

Volumn 46, Issue 12, 2010, Pages 891-899

  Espinosa, G ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; APRIL PROTEIN; B CELL ACTIVATING FACTOR; BELIMUMAB; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE ACID PROTEIN; PLACEBO; PREDNISONE;

ADD ON THERAPY; ANTIBODY TITER; ARTHRALGIA; CLINICAL EFFECTIVENESS; COMPLEMENT BLOOD LEVEL; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; INFECTION; NAUSEA; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA;

ANIMALS; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE;

EID: 79955920959     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.12.1544336     Document Type: Review

References (33)

1. Rahman, A., Isenberg, D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358(9): 929-39. (Pubitemid 351397092)
2. Sanz, I., Lee, F.E. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6(6): 326-37.
3. Schneider, P., MacKay, F., Steiner, V. et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189(11): 1747-56. (Pubitemid 29272691)
4. Bossen, C., Schneider, P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol 2006, 18(5): 263-75. (Pubitemid 44287558)
5. Ding, C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther 2008, 8(11): 1805-14.
6. Daridon, C., Youinou, P., Pers, J.O. BAFF, APRIL, TWE-APRIL: Who's who? Autoimmun Rev 2008, 7(4): 267-71.
7. Youinou, P., Pers, P.O. The late news on BAFF in autoimmune diseases. Autoimmun Rev 2010, 9(12): 804-6.
8. Nardelli, B., Belvedere, O., Roschke, V. et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97(1): 198-204. (Pubitemid 32061261)
9. Gross, J.A., Johnston, J., Mudri, S. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404(6781): 995-9. (Pubitemid 30243593)
10. Thompson, J.S., Bixler, S.A., Qian, F. et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001, 293(5537): 2108-11. (Pubitemid 32848062)
11. Bossen, C., Cachera, T,G., Tardivel, A. et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008, 111(3): 1004-12. (Pubitemid 351213377)
12. Hsu, B.L., Harless, S.M., Lindsley, R.C., Hilbert, D.M., Cancro, M.P. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002, 168(12): 5993-6. (Pubitemid 34620011)
13. Nossal, G.J.V., Pike, B.L. Evidence of the clonal abortion theory of B-lymphocyte tolerance. J Immunol 1975, 141: 904-17.
14. Cancro, M.P., D'Cruz, D., Khamashta, M.A. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009, 119(5): 1066-73.
15. Scholz, J.L., Crowley, J.E., Tomayko, M.M. et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A 2008, 105(40): 15517-22.
16. Mackay, F., Woodcock, S.A., Lawton, P. et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190(11): 1697-710. (Pubitemid 30002351)
17. Schiemann, B., Gommerman, J.L., Vora, K. et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293(5537): 2111-4. (Pubitemid 32848063)
18. Schneider, P., Takatsuka, H., Wilson, A. et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001, 194(11): 1691-7. (Pubitemid 33126819)
19. Cheema, G.S., Roschke, V., Hilbert, D.M., Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44(6): 1313-9. (Pubitemid 32537529)
20. Collins, C.E., Gavin, A.L., Migone, T.S., Hilbert, D.M., Nemazee, D., Stohl, W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: Disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006, 8(1): R6.
21. Hong, S.D., Reiff, A., Yang, H.T. et al. B lymphocyte stimulator expression in and juvenile idiopathic arthritis patients. Arthritis Rheum 2009, 60(11): 3400-9.
22. Stohl, W., Metyas, S., Tan, S.M. et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum 2003, 48(12): 3475-86. (Pubitemid 37531913)
23. Petri, M., Stohl, W., Chatham, W. et al. Association of plasma lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58(8): 2453-9.
24. Baker, K.P., Edwards, B.M., Main, S.H. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48(11): 3253-65. (Pubitemid 37409340)
25. Halpern, W.G., Lappin, P., Zanardi, T., Cai, W., Corcoran, M., Zhong, J., Baker, K.P. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic and toxicologic effects. Toxicol Sci 2006, 91(2): 586-99.
26. Furie, R., Stohl, W., Ginzler, E.M. et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10(5): R109.
27. Wallace, D.J., Stohl, W., Furie, R.A. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61(9): 1168-78.
28. Navarra, S., Guzman, R., Gallacher, A. et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Am Coll Rheum/Assoc Rheum Health Profess Annu Sci Meet (Oct 17-21, Phitdelphia) 2009, Abst 204 B.
29. van Vollenhoven, R.F., Zamani, O., Wallace, D.J. et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE: BLySS-76 study. Ann Rheum Dis 2010, 69(Suppl. 3): 74.
30. Furie, R.A., Petri, M.A., Wallace, D.J. et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009, 61(9): 1143-51.
31. Petri, M.A., Furie, R., Merrill, J.T. et al. Four year experience of belimumab, a BlySspecific inhibitor, in systemic lupus erythematosus (SLE). Am Coll Rheum/Assoc Rheum Health Profess Annu Sci Meet (Oct 17-21, Phitdelphia) 2009, Abst 2069.
32. Tanasescu, C., Gallacher, A., Garcia, M. et al. Belimumab, a BLyS-specific inhibitor, significantly improved physichal functioning, fatigue, and other health-related quality of life (HRQoL) measures in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis 2010, 69(Suppl. 3): 556.
33. Levy, R.A., Ilianova, E., Ionescu, R. et al. Belimumab, a BLyS-specific inhibitor, significantly reduced autoantibodies and normalized low complement in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis 2010, 69(Suppl. 3): 556.